COMPARATIVE EVALUATION OF THE EFFECTIVENESS OF MODERN MEANS OF HYPERCHOLESTEROLEMIA CORRECTION

Authors:

Abstract:

Hypercholesterolemia is one of the most common pathological conditions of the body and plays a particularly important role in the development of cardiovascular diseases, arterial hypertension, type 2 diabetes etc. A total of 846 outpatient records were analyzed. 582 patients were prescribed statins: atorvastatin to 283 patients, rosuvastatin to 261 patients, other statins to 38 patients. The control group consisted of 234 similar patients with uncontrolled hypertension in the group of patients who fully complied with the proposed measures (against the background of 40 mg of atorvastatin), systolic blood pressure significant decreased from 208.5±3.7 to 124.4±6.6 mm Hg, dyastolic blood pressure from 153.6±7.2 to 81.7±5.8 mm Hg, cholesterol from 10.2±1.2 to 5.3±0.6 mmol/l. An analogical changes werealso observed with rosuvastatin: systolic blood pressure decreased from 226.3±9.8 to 138.6±7.8 mm Hg, dyastolic from 164.7±7.3 to 80.5±5.6 mm Hg, cholesterol from 9.6±1.0 to 4.7±0.5 mmol/l. In the group of patients who partially or did not follow the recommended measures (diet and physical activity), only intermediate measurements showed a slight decrease in systolic blood pressure, dyastolic blood pressure and cholesterol (during the co-administration of antihypertensive drugs with statins). Then the measured indicators returned to the initial high level.

Keywords:

hypercholesterolemia nutritional behavior low physical activity

References:

1. Gadzhieva YaG. Rol giperholesterinemii v formirovanii nozostruktury zabolevaemosti naseleniya. Vestnik sovremennoy klinicheskoy meditsiny. 2019;12(1):45–49. [In Russian]
2. Gilyarevskiy SR, Golshmid MV, Kuzmina IM. Rol moshchnyh statinov v sovremennom lechenii bolnykh s vysokim riskom razvitiya oslozhneniy, obuslovlennykh aterosklerozom. Meditsinskiy sovet. 2017;(12):100–104. https://doi.org/10.21518/2079-701X-2017-12-100–104 [In Russian]
3. Zubareva M, Rozhkova T, Gornyakova N, Solovyova E. Effektivnost, bezopasnost i perenosimost terapii rozuvastatinom u bolnykh ochen vysokogo serdechno-sosudistogo riska s pervichnoy giperholesterinemiey. Vrach. 2012; 12: 61–64[In Russian]
4. Karpov YuA. Effektivnost i bezopastnost terapii statinami. Aktualnye voprosy kardiologii. Atm sferA. Novosti kardiologii. 2019; 1:3–12 http://atm-press.ru[In Russian]
5. Katerenchuk ІP, Vakulenko KE, Myakіnkova LO, Shablіy LM. Sіmeyna heterozyhotna hіperholesterynemіya: klіnіchniy vypadok. Kardiologiya: ot nauki k praktike. 2016; 3 (22): 104–117 [In Ukrainian]
6. Safina DD, Ziganshina LE.Statiny i pervichnaya profilaktika serdechno-sosudistykh zabolevaniy: est li smysl? Kazanskiy meditsinskiy zhurnal. 2013; 94(6): 924 –932. [In Russian]
7. Shalnova SA, Nikitin YuP, Simonova GI. Narusheniya lipidnogo obmena kak faktory riska ateroskleroza; V knige: Vse o holesterine: natsionalnyi doklad. Moskva: NCSSH imeni AN Bakuleva RAMN. 2016; 50–59 [In Russian]
8. Sharuho GV, Zolotareva MYu, Feshchenko IP. O profilaktikene infektsionnykh zabolevaniy, svyazannykh s pishchevym faktorom u naseleniya. Tyumenskoy oblasti. Zdravookhraneniye Rossijskoy Federatsii. 2014; 58(4): 54–56 [In Russian]
9. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal. 2016; 37, 39: 2999–3058, https://doi.org/10.1093/eurheartj/ehw272
10. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P; Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010 Dec 16;363(25):2406–15. doi: 10.1056/NEJMoa1009744. Epub 2010 Nov 17. PMID: 21082868.
11. Forouhi NG, Krauss RM, Taubes G, Willett W. Dietary fat and cardiometabolic health: evidence, controversies, and consensus for guidance. BMJ. 2018 Jun 13;361:k2139. PMID: 29898882; PMCID: PMC6053258. DOI: 10.1136/bmj.k2139
12. Giammanco A, Cefalù AB, Noto D, Averna MR. The pathophysiology of intestinal lipoprotein production. Front Physiol. 2015 Mar 20;6:61. doi: 10.3389/fphys.2015.00061. PMID: 25852563; PMCID: PMC4367171.
13. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd- Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/ NLA/PCNA guideline on the management of blood cholesterol: Executive Summary: a report of the American College of Cardiology/ American Heart Association Task Force on clinical practice guidelines. Circulation. 2019;139:e1082–1143. DOI: 10.1161/CIR.0000000000000625
14. Natarajan P, Ray KK, Cannon CP. High – Density Lipoprotein and Coronary Heart Disease Current and Future Therapies. Journal of the American College of Cardiology. 2010; 55 (13): 1283–1299. https://doi.org/10.1016/j.jacc.2010.01.008
15. Standards of medical care in diabetes-2012 / ADS. American Diabetes Association // Diabetes Care. 2012; 35: 11–63. https://doi.org/10.2337/dc12-s011

Publication:

«World of Medicine and Biology» Vol. 18 No. 80 (2022) , с. 38-43
УДК 616.12-009.72: 616.13.002.2-004.6-036.8

DOI:

https://doi.org/10.26724/2079-8334-2022-2-80-38-43